secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-11-10T21:18:54+00:00
Accession:  0001193125-26-455506
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BBOT Q3 net loss $34.2M; BBO-8520 combo ORR 75% at 500mg in G12C-experienced NSCLC
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $315.3M at Sept 30, 2026, expected to fund operations into 2029.
- Q3 net loss $34.2M vs $44.8M a year ago; R&D $29.6M (vs $35.1M) and G&A $7.9M (vs $14.1M, which included a $7.8M BridgeBio Pharma stock charge).
- BBO-8520 plus pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC: 75% ORR at 500mg QD, 53% across dose levels (N=17); AEs mainly GI, favorable liver profile.
- BBO-8520 monotherapy in G12C inhibitor-naive NSCLC: 63% ORR (26/41), 100% DCR (41/41); 21 of 28 eligible patients remained on treatment beyond six months.
- BBO-11818 plus BBO-10203 and cetuximab combination dosing started in KRAS-mutant CRC and PDAC; monotherapy data updates for both expected in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/0001193125-26-455506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/bbot-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer